Core Points - Manulife announced its first dividend distribution for the 2025 fiscal year on October 18, detailing the dividend distribution plan and relevant dates [1] Summary by Sections Dividend Announcement - The dividend distribution base date is set for September 9, 2025, with specific dividend amounts outlined for different fund classes [1] - The dividend amounts are as follows: - Manulife Dividend Bull Mixed A (Code: 162212) has a net asset value of 1.08 yuan and will distribute 0.08 yuan per 10 shares - Manulife Dividend Pioneer Mixed C (Code: 015619) has a net asset value of 1.06 yuan and will distribute 0.06 yuan per 10 shares [1] Key Dates - The record date for dividend entitlement is October 21, 2025, and the cash dividend payment date is October 22, 2025 [1] - Investors opting for reinvestment will have their converted fund shares calculated based on the net asset value on October 22, 2025, with confirmation of the reinvested shares on October 23, 2025 [1] - Investors can start checking their investment status from October 24, 2025 [1] Tax Implications - According to the relevant tax regulations, the fund's dividend distribution to investors is exempt from income tax [1] - The fund will not charge a dividend distribution fee for this dividend [1] - Investors choosing the reinvestment option will not incur subscription fees for the converted fund shares [1]

Core Points - Manulife Fund Management Company announced the suspension of large-scale subscriptions, conversions, and regular investment for the Manulife Dividend Pioneer Mixed Securities Investment Fund starting from October 17, 2025 [1] - The decision aims to protect the interests of fund shareholders and ensure the smooth operation of the fund [1] Fund Details - The fund will limit large subscriptions to amounts exceeding 1 million yuan (excluding 1 million yuan) [1] - The specific time for resuming large subscriptions, regular investments, and conversions will be announced later [1] - The affected sub-funds include: - Manulife Dividend Pioneer Mixed A (Code: 162212) with a subscription limit of 1 million yuan and a conversion limit of 1 million yuan [1] - Manulife Dividend Pioneer Mixed C (Code: 015619) with the same limits as above [1]

Core Viewpoint - The AI Fund Manulife Dividend Pioneer Mixed A (162212) reported a profit of 942,000 yuan for Q2 2025, with a weighted average profit per fund share of 0.0171 yuan, and a net value growth rate of 1.98% during the reporting period [3][17]. Fund Performance - As of July 18, the fund's unit net value was 0.989 yuan, with a one-year cumulative growth rate of 8.09%, ranking 127 out of 133 comparable funds [3][4]. - The fund's three-month cumulative growth rate was 12.64%, ranking 119 out of 138 comparable funds, and the six-month growth rate was 10.13%, ranking 132 out of 138 [4]. Investment Strategy - The fund focuses on long-term investments in pharmaceutical and medical stocks, targeting companies with sustainable dividend capabilities and strong fundamentals [3]. - As of Q2 2025, the fund's main investments were concentrated in sectors such as in-hospital medical devices, equipment and consumables, in-hospital pharmaceuticals, and medical consumer products [3]. Risk Metrics - The fund's three-year Sharpe ratio was -0.0246, ranking 61 out of 105 comparable funds [10]. - The maximum drawdown over the past three years was 27.61%, with the largest single-quarter drawdown occurring in Q1 2022 at 21.42% [12]. Fund Composition - As of Q2 2025, the fund's total assets amounted to 50.68 million yuan [17]. - The top ten holdings included companies such as Aohua Endoscopy, Huatai Medical, and Heng Rui Medicine [19]. Portfolio Management - The fund has maintained a high average stock position of 92.95% over the past three years, compared to a comparable average of 86.95% [15].